

## ***Usage and Measurement of Extended Half-Life Coagulation Factors and Non-Substitutional Therapies***

**Tuesday 28 November 2017, 13.00 to 16.00 hrs**

**Sofitel Brussels Europe**

**Brussels, Belgium**

### **AGENDA**

---

12.00 – 13.00	<b>Registration and light lunch</b>
13.00 – 13.10	<b>Welcome and introduction</b> <i>Prof Michael Makris, Member, EHC Medical Advisory Group</i>
13.10 – 13.30	<b>Current use of EHL and non-substitutional therapies</b> <i>Prof Roger Schutgens, UMC Utrecht</i>
13.30 – 13.50	<b>Monitoring efficacy: Measuring EHL and non-substitutional therapies</b> <i>Dr Annette Bowyer, Sheffield Teaching Hospital</i>
13.50 – 14.10	<b>Monitoring safety: Pharmacovigilance programmes for EHL and non-substitutional therapies</b> <i>Mrs Caroline Voltz-Girolt, EMA</i>
14.10 – 14.30	<b>Assessing value: Comparative assessment of standard treatment vs novel technologies</b> <i>Dr Niamh O'Connell, St James Hospital</i>
14.30 – 14.45	<b>Q&amp;A from the audience</b>
14.45 – 15.30	<b>Panel discussions: what will haemophilia treatment look like in 2027?</b> <i>Prof Cedric Hermans: A clinician's perspective - 15'</i> <i>Dr Deborah Morrison: A payer's perspective – 15'</i> <i>Dr Radoslaw Kaczmarek: A patient's perspective – 15'</i>
15.30 – 15.50	<b>Q&amp;A from the audience</b>
15.50 – 16.00	<b>Conclusions</b> <i>Prof Michael Makris</i>

---

***Coffee will be served throughout the meeting.***